A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance

Imatinib, which is an inhibitor of the BCR-ABL tyrosine kinase, has been a remarkable success for the treatment of Philadelphia chromosome-positive (Ph(+)) chronic myelogenous leukemias (CMLs). However, a significant proportion of patients chronically treated with imatinib develop resistance because...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Gumireddy, Kiranmai, Baker, Stacey J., Cosenza, Stephen C., John, Premila, Kang, Anthony D., Robell, Kimberly A., Reddy, M. V. Ramana, Reddy, E. Premkumar
Formato: Artigo
Idioma:Inglês
Publicado em: National Academy of Sciences 2005
Assuntos:
Biological Sciences
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC546016/
https://ncbi.nlm.nih.gov/pubmed/15677719
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.0408283102
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados